This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
MenB accounts for ~57% of all vaccine-type meningococcal disease cases in persons 16 to 23 years of age in the US1Although uncommon, MenB can be unpredictable with severe consequences including death without warning2,3A critical delay in medical attention: The average time before adolescents and young adults are taken to a hospital is 12 to 19 hours3-5MenB accounts for approximately 50% of all meningococcal disease cases in persons 16 to 23 years of age in the United States1

~20% of those who survive MenB will have permanent or long-term sequelae, such as6,7:

Hearing impairment

Skin scarring

Limb amputation

Neurological dysfunction

Motor impairment

Without a MenB vaccine, your patients may not be protected against all primary serogroups of invasive meningococcal disease6Despite MenB comprising nearly half of all meningococcal cases, only 29.4% of adolescents have received at least one dose of a MenB vaccine. Remember to discuss MenB vaccination at every visit for 16-year-olds, in accordance with CDC recommendations.1,8-10

ACIP recommends vaccination of healthy adolescents or young adults aged 16-23 years (preferred age is 16-18 years) with a 2-dose MenB series on the basis of shared clinical decision-making.10*

Read about the recommendations
LoadingWhen given to healthy adolescents who are not otherwise at increased risk for meningococcal disease, 2 doses of MenB-fHbp should be administered at 0 and 6 months. For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, 3 doses of MenB-fHbp should be administered at 0, 1–2, and 6 months to provide earlier protection and maximize short-term immunogenicity.10
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; fHbp=factor H binding protein; MenACWY=quadrivalent (serogroups A, C, W, Y) meningococcal disease; MenB=serogroup B meningococcal disease.Contact your Pfizer Sales Representative or call a Vaccine Specialist at ​​​1-800-666-7248.Example TextReferences:1. Enhanced meningococcal disease surveillance report, 2021. Centers for Disease Control and Prevention website. Accessed November 6, 2023. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf. 2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607. 3. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 4. Brandtzaeg P. Pathogenesis and pathophysiology of invasive meningococcal disease. In: Frosch M, Maiden MCJ, eds. Handbook of Meningococcal Disease: Infection Biology, Vaccination, Clinical Management. Wiley-VCH; 2006:427-480. 5. van Deuren M, Brandtzaeg P, van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13(1):144-166. 6. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Members of Canadian Immunization Monitoring Program, Active (IMPACT). The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25. 7. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;12(3):e502-e509. 8. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed April 1, 2021. 9. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years — National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912–919. 
10. Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2023. Centers for Disease Control and Prevention website. Updated September 27, 2023. Accessed November 6, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. 11. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 12. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 13. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130. 14. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 15. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.ReferencesLorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.
Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
 Find out about TruSupportLoading
Why adolescents and young adults?

Typical adolescent and young adult behaviors increase MenB risk.8,11-13

Learn more about MenB
Loading
The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.14,15

 See the scienceLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TRU-USA-3196
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.